Leukine (sargramostim) / Partner Therap 
Welcome,         Profile    Billing    Logout  
 449 Diseases   58 Trials   58 Trials   3605 News 


«12...13141516171819202122232425»
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
    Trial primary completion date:  Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma (clinicaltrials.gov) -  Mar 9, 2015   
    P2,  N=42, Completed, 
    Trial primary completion date: Dec 2006 --> Sep 2013
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Zeltherva (galinpepimut-S) / SELLAS Life Sciences
    Trial completion:  Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms (clinicaltrials.gov) -  Feb 27, 2015   
    P=N/A,  N=16, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
    Combination therapy, Metastases:  PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) -  Feb 6, 2015   
    P1,  N=51, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Jan 2015 --> Jan 2016
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial primary completion date:  Study of the Safety & Efficacy of Leukine (clinicaltrials.gov) -  Feb 2, 2015   
    P2,  N=40, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> Jan 2016
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Roche
    Trial primary completion date, Combination therapy:  Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (clinicaltrials.gov) -  Jan 29, 2015   
    P2,  N=130, Active, not recruiting, 
    Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: Aug 2015 --> Aug 2016
  • ||||||||||  Leukine (sargramostim) / Partner Therap, Yervoy (ipilimumab) / BMS
    Trial initiation date:  Ipilimumab and GMCSF Immunotherapy for Prostate Cancer (clinicaltrials.gov) -  Jan 12, 2015   
    P2,  N=54, Not yet recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Dec 2014 Initiation date: Aug 2014 --> Mar 2015
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial completion, Trial primary completion date:  GPAD-2: Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease (clinicaltrials.gov) -  Dec 24, 2014   
    P2,  N=159, Completed, 
    N=42 --> 21 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2010 --> Dec 2009 Active, not recruiting --> Completed | Trial primary completion date: Jan 2013 --> Mar 2014
  • ||||||||||  BiovaxID (dasiprotimut-T) / National Cancer Institute, Accentia
    Trial primary completion date:  Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma (clinicaltrials.gov) -  Dec 19, 2014   
    P2,  N=26, Active, not recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Aug 2005
  • ||||||||||  BiovaxID (dasiprotimut-T) / National Cancer Institute, Accentia
    Enrollment closed, Trial primary completion date:  Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma (clinicaltrials.gov) -  Dec 17, 2014   
    P2,  N=26, Active, not recruiting, 
    Active, not recruiting --> Completed | N=54 --> 40 Completed --> Active, not recruiting | Trial primary completion date: Aug 2005 --> Jun 2017
  • ||||||||||  Recentin (cediranib) / AstraZeneca
    Trial primary completion date, Monotherapy, Metastases:  Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) -  Dec 9, 2014   
    P2,  N=70, Recruiting, 
    Not yet recruiting --> Recruiting Trial primary completion date: Jun 2015 --> Apr 2016
  • ||||||||||  UV1 / Ultimovacs
    Enrollment closed, Trial primary completion date, Metastases:  A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer (clinicaltrials.gov) -  Dec 9, 2014   
    P1/2,  N=21, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jul 2015
  • ||||||||||  Enrollment open:  HER2-Peptide Vaccination of Patients With Solid Tumors (clinicaltrials.gov) -  Dec 5, 2014   
    P1,  N=12, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Jul 2015 Not yet recruiting --> Recruiting
  • ||||||||||  temozolomide / Generic mfg.
    Enrollment open, Immunomodulating:  GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients (clinicaltrials.gov) -  Oct 24, 2014   
    P1,  N=20, Recruiting, 
    Recruiting --> Suspended Not yet recruiting --> Recruiting
  • ||||||||||  temozolomide / Generic mfg.
    Trial initiation date, Immunomodulating:  GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients (clinicaltrials.gov) -  Oct 15, 2014   
    P1,  N=20, Not yet recruiting, 
    Trial primary completion date: Oct 2013 --> Nov 2014 Initiation date: Jul 2014 --> Oct 2014
  • ||||||||||  SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
    Trial primary completion date:  Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma (clinicaltrials.gov) -  Sep 28, 2014   
    P1,  N=9, Active, not recruiting, 
    Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Sep 2014 --> May 2014
  • ||||||||||  Leukine (sargramostim) / Partner Therap
    Trial primary completion date:  Leukine (Sargramostim) for Parkinson's Disease (clinicaltrials.gov) -  Sep 19, 2014   
    P1,  N=32, Recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: May 2014 --> Sep 2014 | Trial primary completion date: May 2020 --> Sep 2020 Trial primary completion date: Jan 2015 --> Sep 2015